Page last updated: 2024-11-10

menaquinone 6

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

menaquinone 6: RN given refers to (all-E)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5283547
SCHEMBL ID244452
MeSH IDM0125359

Synonyms (32)

Synonym
BIDD:PXR0122
menaquinone-6
LMPR02030001
vitamin k 2
mk-6
menaquinone(6)
84-81-1
(all-e)-2-(3,7,11,15,19,23-hexamethyl-2,6,10,14,18,22-tetracosahexaenyl)-3-methyl-1,4-naphthalenedione
2-[(2e,6e,10e,14e,18e)-3,7,11,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaenyl]-3-methylnaphthalene-1,4-dione
1,4-naphthalenedione, 2-(3,7,11,15,19,23-hexamethyl-2,6,10,14,18,22-tetracosahexaenyl)-3-methyl-, (all-e)-
farnoquinone, (all-e)-
farnoquinone
vitamin k2(30)
2-methyl-3-farnesyl-farnesyl-1,4-naphthoquinone
71anl51tla ,
menaquinone 6
unii-71anl51tla
vitamin mk6
menaquinone k6
2-difarnesyl-3-methyl-1,4-naphthoquinone
1,4-naphthalenedione, 2-((2e,6e,10e,14e,18e)-3,7,11,15,19,23-hexamethyl-2,6,10,14,18,22-tetracosahexaen-1-yl)-3-methyl-
1,4-naphthalenedione, 2-((2e,6e,10e,14e,18e)-3,7,11,15,19,23-hexamethyl-2,6,10,14,18,22-tetracosahexaenyl)-3-methyl-
mk 6
menaquinone 6 [mi]
SCHEMBL244452
PFRQBZFETXBLTP-RCIYGOBDSA-N
farnochinon
DB14936
DTXSID801018975
Q27265949
2-((2e,6e,10e,14e,18e)-3,7,11,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaen-1-yl)-3-methylnaphthalene-1,4-dione
1,4-naphthalenedione,2-[(2e,6e,10e,14e,18e)-3,7,11,15,19,23-hexamethyl-2,6,10,14,18,22-tetracosahexaenyl]-3-methyl-

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Clinical and comparative study of the efficacy and adverse events of Menatetrenone-4."( Efficacy and safety of Menatetrenone-4 postmenopausal Thai women.
Bonjongsat, A; Boonsangsom, P; Bunyaratavej, N; Kittimanon, N; Penkitti, P; Yunoi, S, 2001
)
0.31
" The no observed adverse effect level (NOAEL) of MK-7, when administered orally to rats for 90 days, was considered to be equal to 10 mg/kg body weight/day, the highest dose tested, based on lack of toxicity during the 90-day study period."( Safety and toxicological evaluation of a synthetic vitamin K2, menaquinone-7.
Møller, M; Preston, T; Pucaj, K; Rasmussen, H, 2011
)
0.37
" Adverse reaction analysis showed that there seemed to be higher adverse reaction rates in the vitamin K2 group (RR = 1."( Efficacy and safety of vitamin K2 for postmenopausal women with osteoporosis at a long-term follow-up: meta-analysis and systematic review.
Han, S; Wu, D; Zhang, W; Zhou, M, 2022
)
0.72
" Vitamin K2 supplementation is beneficial and safe in the treatment of osteoporosis for postmenopausal women."( Efficacy and safety of vitamin K2 for postmenopausal women with osteoporosis at a long-term follow-up: meta-analysis and systematic review.
Han, S; Wu, D; Zhang, W; Zhou, M, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
"A simple and sensitive assay method for a pharmacokinetic study of Menaquinone-4 in dogs was established using HPLC with fluorescence detection following extraction with organic solvent."( Pharmacokinetic characterization of menaquinone-4 in dogs by sensitive HPLC determination.
Kaneko, K; Kikuchi, K; Sano, Y; Tadano, K; Yuzuriha, T, 1993
)
0.29
" Plasma half-life of menatetrenone after administration as the lipid emulsions prepared by HCO with 10 oxyethylene units (SO/HCO10) was similar to that after the administration as SO/egg yolk phosphatides (SO/EYP), but was shorter than that as the lipid emulsions prepared by HCOs with > 20 oxyethylene units (SO/HCO20, SO/HCO30, SO/HCO60, SOHC and SO/HCO100)."( Effect of oxyethylene moieties in hydrogenated castor oil on the pharmacokinetics of menatetrenone incorporated in O/W lipid emulsions prepared with hydrogenated castor oil and soybean oil in rats.
Iwakawa, S; Noto, H; Sakaeda, T; Teshima, Y; Ueda, K; Yamashita, C; Yamazaki, Y, 2003
)
0.32
" The plasma half-life of menatetrenone incorporated in the oil particles prepared with SO and dipalmitoylphosphatidylcholine (DPPC) (SO/DPPC) was longer than that prepared with SO and eggyolk phosphatides (EYP) (SO/EYP) by 3 fold, while those of menatetrenone as oil particles prepared with SO and either dilauroyl phosphatidylcholine (DLPC), dimyristoyl phosphatidylcholine (DMPC), distearoyl phosphatidylcholine (DSPC), dioleoyl phosphatidylcholine (DOPC) or dilinoleoyl phosphatidylcholine (DLoPC) (SO/DLPC, SO/DMPC, SO/DSPC, SO/DOPC and SO/DLoPC, respectively) were similar to that of menatetrenone as SO/EYP."( Effect of acyl chains of phosphatidylcholines on the pharmacokinetics of menatetrenone incorporated in O/W lipid emulsions prepared with phosphatidylcholines and soybean oil in rats.
Fujimoto, M; Iwakawa, S; Noto, H; Sakaeda, T; Ueda, K, 2004
)
0.32
" The half-life of menatetrenone in plasma when oxyethylene units made up less than 30% of the Pluronic (SO/PL101 and SO/PP103) was similar to that for SO/egg yolk phosphatides (SO/EYP), but longer than that when oxyethylene units composed more than 40% of the Pluronic (SO/PP104 and SO/PF108, by 3- and 10-fold, respectively)."( Effect of oxyethylene numbers on the pharmacokinetics of menatetrenone incorporated in oil-in-water lipid emulsions prepared with polyoxyethylene-polyoxypropylene block copolymers and soybean oil in rats.
Iwakawa, S; Kawaguchi, Y; Ueda, K, 2008
)
0.35

Compound-Compound Interactions

ExcerptReferenceRelevance
"The relationship between bone turnover and bone tissue and material properties was examined in ovariectomized (OVX) rats treated with risedronate in combination with or without vitamin K2."( Regulation of mineral-to-matrix ratio of lumbar trabecular bone in ovariectomized rats treated with risedronate in combination with or without vitamin K2.
Ikeda, S; Ito, M; Nakamura, T; Otomo, H; Phipps, RJ; Sakai, A; Tanaka, S, 2004
)
0.32
" In the present study, we demonstrated the effects of vitamin K(2) alone or in combination with pamidronate in an arterial calcification model induced using inorganic phosphate in cultured bovine aortic smooth muscle cells (BASMCs)."( Treatment with vitamin k(2) combined with bisphosphonates synergistically inhibits calcification in cultured smooth muscle cells.
Saito, E; Sato, F; Seyama, Y; Sugitani, H; Wachi, H, 2007
)
0.34
"Calcium deposition assay and von Kossa staining showed that calcification could be inhibited in a dose-dependent manner by treatment with vitamin K(2) alone, and that its inhibitory effect was enhanced when combined with pamidronate."( Treatment with vitamin k(2) combined with bisphosphonates synergistically inhibits calcification in cultured smooth muscle cells.
Saito, E; Sato, F; Seyama, Y; Sugitani, H; Wachi, H, 2007
)
0.34
"Taken together, our study suggests that vitamin K(2) in combination with pamidronate synergistically inhibits arterial calcification via the increased expression of tropoelastin, which would be a useful marker for developing effective therapeutic or prophylactic agents for arterial calcification."( Treatment with vitamin k(2) combined with bisphosphonates synergistically inhibits calcification in cultured smooth muscle cells.
Saito, E; Sato, F; Seyama, Y; Sugitani, H; Wachi, H, 2007
)
0.34
"To investigate the effects of vitamin K2 (Vit K2) alone or in combination with etidronate and risedronate on bone loss, osteoclast induction, and inflammation in patients with rheumatoid arthritis (RA)."( Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results.
Morishita, M; Nagashima, M; Takahashi, H; Takenouchi, K; Wauke, K, 2008
)
0.35
"Vit K2 alone or in combination with bisphosphonates for treatment of osteoporosis in patients with RA may inhibit osteoclast induction via decreases in levels of RANKL."( Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results.
Morishita, M; Nagashima, M; Takahashi, H; Takenouchi, K; Wauke, K, 2008
)
0.35
" We aimed to evaluate the effects of risedronate alone or combined with vitamin K2 on serum ucOC, OC, and incidence of vertebral fractures in elderly osteoporotic patients."( Effects of risedronate alone or combined with vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis.
Aizawa, T; Chida, S; Ebina, T; Hongo, M; Ishikawa, Y; Kasukawa, Y; Miyakoshi, N; Nozaka, K; Saito, H; Shimada, Y, 2014
)
0.4
"To explore the clinical effect of zoledronic acid combined with vitamin K2 regimen in percutaneous vertebroplasty for multi-segment osteoporotic vertebral compression fractures(OVCFs)."( [Clinical application of zoledronic acid combined with vitamin K2 in percutaneous vertebroplasty for multi-segment osteoporotic vertebral compression fractures].
Huang, Y; Wu, D, 2020
)
0.56
" According to whether zoledronic acid combined with vitamin K2 was used to treat osteoporosis after surgery, the patients were divided into control group and experimental group."( [Clinical application of zoledronic acid combined with vitamin K2 in percutaneous vertebroplasty for multi-segment osteoporotic vertebral compression fractures].
Huang, Y; Wu, D, 2020
)
0.56
"Zoledronic acid injection combined with vitamin K2 regimen can be used for anti-osteoporosis treatment of OVCFs vertebroplasty."( [Clinical application of zoledronic acid combined with vitamin K2 in percutaneous vertebroplasty for multi-segment osteoporotic vertebral compression fractures].
Huang, Y; Wu, D, 2020
)
0.56

Bioavailability

ExcerptReferenceRelevance
" The relative bioavailability of MKH after the administration of the prodrugs was assessed from the area under the plasma concentration of MKO vs."( Vitamin K prodrugs: 2. water-soluble prodrugs of menahydroquinone-4 for systemic site-specific delivery.
Hanada, M; Karube, Y; Matsunaga, K; Matsushima, Y; Oishi, R; Sendo, T; Takata, J, 1995
)
0.29
"All compounds showed linear pharmacokinetics, and significant bioavailability of MKH was also observed following the administration of 1 (188%), 2 (87%) and 3 (135%)."( Vitamin K prodrugs: 2. water-soluble prodrugs of menahydroquinone-4 for systemic site-specific delivery.
Hanada, M; Karube, Y; Matsunaga, K; Matsushima, Y; Oishi, R; Sendo, T; Takata, J, 1995
)
0.29
" It is concluded that the bioavailability of membrane-bound phylloquinone is extremely poor and may depend on other food components, notably fat."( Effect of food composition on vitamin K absorption in human volunteers.
Gijsbers, BL; Jie, KS; Vermeer, C, 1996
)
0.29
"The purpose of this investigation was to determine the effects of fat content and frequency of meals on the oral bioavailability of menatetrenone (2-methyl-3-all-trans-tetraprenyl-1,4-naphthoquinone), a vitamin K2 with four isoprene units."( Effect of dietary fat content on oral bioavailability of menatetrenone in humans.
Ishii, M; Kanamaru, M; Kohno, K; Nagashima, S; Niwa, M; Sassa, T; Tomono, Y; Uematsu, T; Yamato, C, 1996
)
0.29
" Therefore, the observed differences between K1 and MK-4 with respect to inhibition of arterial calcification may be explained by both differences in their tissue bioavailability and cofactor utilization in the reductase/carboxylase reaction."( Tissue-specific utilization of menaquinone-4 results in the prevention of arterial calcification in warfarin-treated rats.
De Mey, JG; Schurgers, LJ; Soute, BA; Spronk, HM; Thijssen, HH; Vermeer, C,
)
0.13
" The 18O-labeled MK-4 was rapidly and remarkably well absorbed into the cells and metabolized to the epoxide form via a hydroquinone form as compared to the 18O-labeled PK."( Comparative uptake, metabolism, and utilization of menaquinone-4 and phylloquinone in human cultured cell lines.
Mizuguchi, Y; Murakami, A; Nakagawa, K; Okano, T; Suhara, Y, 2006
)
0.33
" Knowledge of the relative bioavailability of multiple vitamin K forms was also poor."( Vitamin K nutrition, metabolism, and requirements: current concepts and future research.
Booth, SL; Fu, X; Shearer, MJ, 2012
)
0.38
" However, little is known about the bioavailability of nutritional MK-4."( Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women.
Sato, T; Schurgers, LJ; Uenishi, K, 2012
)
0.38
" MK-7 was well absorbed and reached maximal serum level at 6 h after intake and was detected up to 48 h after intake."( Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women.
Sato, T; Schurgers, LJ; Uenishi, K, 2012
)
0.38
" However, menaquinone-7 (MK-7) has greater bioavailability and efficacy than MK-4 after oral administration."( Menaquinone-7 as a novel pharmacological therapy in the treatment of rheumatoid arthritis: A clinical study.
Abdel-Rahman, MS; Ahmed, S; Alkady, EA, 2015
)
0.42
" Menaquinone-7 has greater bioavailability than other forms of vitamin K, which has led to increasing sales and use of menaquinone-7 supplements."( US Pharmacopeial Convention safety evaluation of menaquinone-7, a form of vitamin K.
Marles, RJ; Oketch-Rabah, HA; Roe, AL, 2017
)
0.46
" MK-7 has higher efficacy due to its higher bioavailability and longer half-life than other vitamin K homologs."( MK-7 and Its Effects on Bone Quality and Strength.
Inaba, N; Sato, T; Yamashita, T, 2020
)
0.56
" Ongoing initiatives aimed at modulating the colonic microbiota of cancer patients may consider targeted delivery of poorly absorbed selective bacterial growth agents."( Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients.
Abdur-Rashid, K; Al, KF; Anderson, A; Burton, JP; Chanyi, RM; Chin, J; Chmiel, JA; Daisley, BA; Dewar, M; Gibbons, S; Nair, SM; Reid, G; Wilcox, H, 2020
)
0.56
" Among these, MK7 is the most efficient in terms of bioavailability and biological effect."( Carboxylative efficacy of trans and cis MK7 and comparison with other vitamin K isomers.
Cirilli, I; Dludla, PV; Kaesler, N; Marcheggiani, F; Orlando, P; Silvestri, S; Tiano, L, 2022
)
0.72
" Especially, menaquinone-7 has a higher bioavailability and a longer half-life than other vitamin Ks in the human body."( Characterization of K-binding factor involved in water-soluble complex of menaquinone-7 produced by Bacillus subtilis natto.
Chatake, T; Inoue, R; Morishima, K; Murakami, R; Ohsugi, T; Okuda, A; Sugiyama, M; Sumi, H; Takata, T; Yanagisawa, Y, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" In the menatetrenone treated group, the menatetrenone was intramuscularly given in a dosage of 10 mg immediately after closure of the abdominal wound and every 24 hours for two days."( [The effect of menatetrenone on peritoneal adhesion].
Esato, K; Kanesada, H; Marumoto, M; Morita, N; Okino, M; Tomie, H, 1991
)
0.28
" In addition, 2,3-epoxy-MQ-4 was identified in the liver of rats which were pretreated with warfarin and then dosed with [14C]MQ-4."( Identification of menaquinone-4 metabolites in the rat.
Fujita, T; Hashimoto, K; Sato, T; Satoh, T; Shimada, K; Tadano, K; Yuzuriha, T, 1989
)
0.28
" The level of radioactivity in the liver after dosing with L was about 2 times higher than in dosing with H, and a similar result was obtained in the hepatic microsomal fraction, a target of MQ-4."( Effect of solubilizer on the metabolic fate of menaquinone-4 in rats.
Fujita, T; Ikeuchi, T; Sato, T; Tadano, K; Yuzuriha, T, 1989
)
0.28
" Milk/blood concentration ratios at 6 and 24h after dosing were 13."( The placental and mammary transport of [14C]menaquinone-4 in rats.
Miyake, Y; Tadano, K; Yuzuriha, T, 1989
)
0.28
"Patients (40 cases) were treated with daily dosage of warfarin of 2-7 mg after being undergone artificial valve replacements."( Anticoagulant effects of warfarin and kinetics of K vitamins in blood and feces.
Ishibashi, M; Kariyazono, H; Nakamura, K; Saigenji, H; Shimokawa, S; Taira, A; Toyohira, H, 1994
)
0.29
" The mean AUC for oral dosing in the soft-capsule formulation was 13."( Pharmacokinetic characterization of menaquinone-4 in dogs by sensitive HPLC determination.
Kaneko, K; Kikuchi, K; Sano, Y; Tadano, K; Yuzuriha, T, 1993
)
0.29
" Both UQ and MK contents decreased with increasing NaCIO dosage and it seems that there is more resistance from UQ compared to MK."( Microbial community in biofilm on membrane surface of submerged MBR: effect of in-line cleaning chemical agent.
Ahn, KH; Cho, JW; Lim, BR; Song, KG, 2005
)
0.33
" The results of two dose-response studies have indicated that the amount of vitamin K needed for optimal gamma-carboxylation of osteocalcin is significantly higher than what is provided through diet alone and that current dosage recommendations should be increased to optimize bone mineralization."( Vitamin K in the treatment and prevention of osteoporosis and arterial calcification.
Adams, J; Pepping, J, 2005
)
0.33
" In two studies, 6-month-old rats were ovariectomized, except for sham-ovariectomy controls (Sham), and dosed orally with vehicle, 30 mg/kg vitamin K2, 1 mg/kg raloxifene, or the combination of K + Ral for 6 weeks following surgery."( Raloxifene and vitamin K2 combine to improve the femoral neck strength of ovariectomized rats.
Iwamoto, J; Rowley, E; Sato, M; Schmidt, A; Stanfield, L; Takeda, T; Yeh, JK, 2005
)
0.33
"The purpose of the present study was to examine the effect of pretreatment with risedronate and/or vitamin K2 and treatment continuation with reduced dosing frequency of the drugs on the early cancellous bone loss induced by ovariectomy (OVX) in rats."( Beneficial effect of pretreatment and treatment continuation with risedronate and vitamin K2 on cancellous bone loss after ovariectomy in rats: a bone histomorphometry study.
Iwamoto, J; Sato, Y; Shen, CL; Takeda, T; Yeh, JK, 2006
)
0.33
" The dosing period was 4 weeks."( Additive effect of vitamin K2 and risedronate on long bone mass in hypophysectomized young rats.
Iwamoto, J; Sato, Y; Takeda, T; Yeh, JK, 2007
)
0.34
" Recent epidemiological studies provide data on the effectiveness of different administration routes and dosing schemes."( Vitamin K, an update for the paediatrician.
De Bruyne, R; Van Biervliet, S; Van De Velde, S; Van Winckel, M, 2009
)
0.35
" The primary aim was to confirm the superiority of active drug to placebo concerning disease-free survival (DFS), and the secondary aim was to evaluate dose-response relationship."( Effect of vitamin K2 on the recurrence of hepatocellular carcinoma.
Araki, Y; Ichinose, M; Ikeda, H; Ishikawa, A; Izumi, N; Kasugai, H; Katamoto, T; Kawabe, T; Kawazoe, S; Kikuchi, K; Kobashi, H; Koike, Y; Kojiro, M; Kokuryu, H; Koyanagi, N; Kudo, M; Kuroda, H; Kuromatsu, R; Masaki, N; Mizuta, T; Nomoto, M; Oka, H; Omata, M; Osaki, Y; Osawa, T; Saito, K; Sakaida, I; Sakisaka, S; Seike, M; Seki, T; Shiina, S; Shiratori, Y; Tagawa, K; Toyota, J; Tsuji, K; Ueno, Y; Yamamoto, K; Yamashita, T; Yoshida, H, 2011
)
0.37
" We were therefore interested to study the dose-response effects of extra intake of menaquinones on the carboxylation of the extra-hepatic Gla-proteins."( Low-dose menaquinone-7 supplementation improved extra-hepatic vitamin K status, but had no effect on thrombin generation in healthy subjects.
Cranenburg, EC; Knapen, MH; Magdeleyns, EJ; Schurgers, LJ; Smit, E; Teunissen, KJ; Theuwissen, E; Vermeer, C, 2012
)
0.38
"Twenty children on a stable dosage of glucocorticoids were randomly divided into two groups (alfacalcidol or menatetrenone)."( Prevention of bone loss in children receiving long-term glucocorticoids with calcium and alfacalcidol or menatetrenone.
Deekajorndech, T; Pisutikul, K; Rianthavorn, P; Suphapeetiporn, K; Tepmongkol, S, 2012
)
0.38
"Medline, Embase and Cochrane Register of Controlled trials were searched for randomized controlled trials where vitamin K2 or its analogues, in any dosage were compared to placebo or No vitamin K2, for participants of any age or sex."( Role of vitamin K2 in preventing the recurrence of hepatocellular carcinoma after curative treatment: a meta-analysis of randomized controlled trials.
Amir, M; Badshah, MB; Kazi, AN; Rahman, S; Riaz, H; Riaz, IB; Riaz, T, 2012
)
0.38
"Menaquinone-4 (MK-4) administered at a pharmacological dosage of 45 mg/day has been used for the treatment of osteoporosis in Japan."( Low-dose vitamin K2 (MK-4) supplementation for 12 months improves bone metabolism and prevents forearm bone loss in postmenopausal Japanese women.
Aoki, M; Gando, Y; Ishimi, Y; Koitaya, N; Komatsu, M; Miyachi, M; Morishita, K; Morita, A; Nishide, Y; Sekiguchi, M; Tousen, Y; Watanabe, F; Yamauchi, J, 2014
)
0.4
"Warfarin is characterized by a large inter-individual variability in dosage requirement."( Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy.
Akimoto, T; Hayashi, H; Hirai, K; Inoue, K; Itoh, K; Izumiya, K; Moriwaki, H; Suzuki, M; Tanaka, M; Tsuji, D; Yamada, Y; Yoshizawa, M, 2015
)
0.42
" In contrast, plasma VK1 and MK-4 concentrations were not significantly associated with warfarin dosage in patients."( Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy.
Akimoto, T; Hayashi, H; Hirai, K; Inoue, K; Itoh, K; Izumiya, K; Moriwaki, H; Suzuki, M; Tanaka, M; Tsuji, D; Yamada, Y; Yoshizawa, M, 2015
)
0.42
" The CYP4F2 polymorphism is poorly associated with inter-individual variability of warfarin dosage requirement."( Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy.
Akimoto, T; Hayashi, H; Hirai, K; Inoue, K; Itoh, K; Izumiya, K; Moriwaki, H; Suzuki, M; Tanaka, M; Tsuji, D; Yamada, Y; Yoshizawa, M, 2015
)
0.42
" Study 1 was a double-blind, randomized controlled dose-finding trial; 60 postmenopausal women aged 50-69 y were allocated to one of four dosage group and consumed 0, 50, 100, or 200 μg menaquinone-7 daily for 4 wk, respectively, with a controlled diet in accordance with recommended daily intakes for 2010 in Japan."( Low-Dose Daily Intake of Vitamin K(2) (Menaquinone-7) Improves Osteocalcin γ-Carboxylation: A Double-Blind, Randomized Controlled Trials.
Inaba, N; Sato, T; Yamashita, T, 2015
)
0.42
" MK-7 is able to modulate immune and inflammatory reactions in the dose-response inhibition of TNF-α, IL-1α, and IL-1β gene expression and protein production by the healthy hMDMs in vitro."( Inhibition of TNF-α, IL-1α, and IL-1β by Pretreatment of Human Monocyte-Derived Macrophages with Menaquinone-7 and Cell Activation with TLR Agonists In Vitro.
Badmaev, V; Ho, CT; Lee, PS; Maresz, K; Mehta, DS; Pan, MH; Popko, J; Stohs, SJ; Wu, JC, 2016
)
0.43
" The predicted warfarin-binding site was verified by shifted dose-response curves of specified mutated residues."( Warfarin and vitamin K compete for binding to Phe55 in human VKOR.
Biswas, A; Czogalla, KJ; Höning, K; Hornung, V; Liphardt, K; Oldenburg, J; Watzka, M, 2017
)
0.46
" On the basis of this conclusion, US Pharmacopeia monographs have been developed to establish quality standards for menaquinone-7 as a dietary ingredient and as a dietary supplement in various dosage forms."( US Pharmacopeial Convention safety evaluation of menaquinone-7, a form of vitamin K.
Marles, RJ; Oketch-Rabah, HA; Roe, AL, 2017
)
0.46
" Dosage adjustments based on renal function in the package information are effective in controlling the trough and peak concentrations in similar ranges."( [Clinical Pharmacometrics for Rational Drug Treatment].
Yano, I, 2019
)
0.51
"Two consecutive experiments, each lasting 4 weeks, were required to modify the dosing schedule of warfa-rin and VK1 and to adapt it to the Wistar rats used."( Experimental Model of Subclinical Vitamin K Deficiency.
Gancheva, S; Ghenev, P; Kitanova, M; Zhelyazkova-Savova, M, 2020
)
0.56
"The original dosing schedule induced VK deficiency, manifested by arterial calcifications and dramatic changes in carboxyl-ated and uncarboxylated osteocalcin."( Experimental Model of Subclinical Vitamin K Deficiency.
Gancheva, S; Ghenev, P; Kitanova, M; Zhelyazkova-Savova, M, 2020
)
0.56
"816), were found to be inversely associated with the risk of pancreatic cancer in a nonlinear dose-response manner (all P values for nonlinearity < 0."( Dietary Vitamin K Intake and the Risk of Pancreatic Cancer: A Prospective Study of 101,695 American Adults.
Cheng, L; Gong, JP; Hu, JJ; Li, QJ; Peng, Y; Sun, WP; Wu, JJ; Yang, PF; Yu, DW; Zhong, GC, 2021
)
0.62
"MK-7 supplementation at recommended dosage does not affect vitamin K-dependent coagulation factors' coagulation activity, and does not enhance the carboxylation of prothrombin in healthy individuals."( Vitamin K2 (Menaquinone-7) supplementation does not affect vitamin K-dependent coagulation factors activity in healthy individuals.
Cheng, G; Liu, J; Ren, R; Tan, J, 2021
)
0.62
" However, further randomized clinical studies are needed to assess the safety and the adequate dosage to prevent these CKD complications."( Role of Vitamin K in Chronic Kidney Disease: A Focus on Bone and Cardiovascular Health.
Andreucci, M; Bellone, F; Bolignano, D; Carullo, N; Casarella, A; Cinquegrani, M; Coppolino, G; De Sarro, G; Mandraffino, G; Nicotera, R; Presta, P; Prunestì, M; Squadrito, G; Vocca, C, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,576)

TimeframeStudies, This Drug (%)All Drugs %
pre-199035 (0.98)18.7374
1990's83 (2.32)18.2507
2000's542 (15.16)29.6817
2010's2409 (67.37)24.3611
2020's507 (14.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 15.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index15.17 (24.57)
Research Supply Index8.22 (2.92)
Research Growth Index5.63 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index3.00 (0.95)

This Compound (15.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials123 (3.42%)5.53%
Reviews169 (4.69%)6.00%
Case Studies17 (0.47%)4.05%
Observational6 (0.17%)0.25%
Other3,285 (91.25%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]